Please login to the form below

Not currently logged in
Email:
Password:

GalNAc

This page shows the latest GalNAc news and features for those working in and with pharma, biotech and healthcare.

Pfizer signs $900m-plus deal with WAVE for metabolic R&D

Pfizer signs $900m-plus deal with WAVE for metabolic R&D

This approach will be combined with a liver-targeting delivery technology in development at Pfizer that involves binding RNA drugs to the amno acid N-acetylgalactosamine (GalNAc). ... The deal gives WAVE scope to use GalNAc in certain projects that lie

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Gene therapy Gene therapy

    targets. The overt focus on liver disease has led to one new system for delivering siRNA to the liver, called GalNAc. ... GalNAc uses a specific sugar group attached to chemically-modified siRNA to target liver cells.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics